30 results about "TNF inhibitor" patented technology

Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.

The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.

Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, and brain injury are described. More particularly, TNF blocking agents that target TNF-receptor interactions and the effects of downstream secreted cytokines associated with an inflammatory cascade are described. Such TNF blocking agents are administered directly to the brain by, for example, intraparenchymal administration, intracerebroventricular administration, or administration into a cerebral artery. Devices described include therapy delivery devices comprising a reservoir capable of housing a TNF blocking agent and a catheter operably coupled to the device and adapted to deliver the TNF blocking agent to a target site within a subject.

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

The invention provides an application of japonicone A (chemical structural formula I) in preparation of tumor necrosis factor (TNF) inhibitor drugs. The japonicone A is inula japonica extract. In the invention, by adopting a reverse docking technology for virtual screening, the result shows that TNF-alpha is potential binding protein of the japonicone A; by adopting a BIACORE technology, the result shows that the japonicone A can be directly combined with TNF-alpha coupled on a chip, and can inhibit the combination of the TNF-alpha and the TNF-R (receptor) coupled on a sensor chip; and furthermore, an experiment confirms that the japonicone A can be directly combined with the TNF-alpha and can inhibit the interaction of the TNF-alpha and the TNF-R, thus the japonicone A can be used for preparing TNF inhibitor drugs. The drug provided by the invention is a pharmaceutical composition prepared from a medicinal carrier and the japonicone A used as an active ingredient. The pharmaceutical composition can be used for treating TNF-related diseases such as osteoarthropathy, asthma, bronchitis, allergic rhinitis and the like, thereby providing a new way for treating the diseases and obtaining greater clinical application values.

The invention discloses an inhibitor of mitogen protein kinase p38 as well as a preparation method and application of the inhibitor. The inhibitor is an amino nicotinamide compound or an amino pyrazinamide compound. The preparation method mainly comprises the following steps: nitrifying 6-hydroxyl nicotinic acid to generate 5-nitro-6-hydroxyl nicotinic acid; treating 5-nitro-6-hydroxyl nicotinic acid with phosphorus oxybromide so as to convert 5-nitro-6-hydroxyl nicotinic acid into 5-nitro-6-bromonicotinic acid; carrying out Suzuki coupling reaction on 5-nitro-6-bromonicotinic acid to generate 5-nitro-6-aryl nicotinic acid; reacting 5-nitro-6-aryl nicotinic acid with oxalyl chloride to obtain 5-nitro-6-aryl nicotinamide; and carrying out hydrogenation reduction on a nitro group to obtain 5-amino-6-aryl nicotinamide. According to the invention, the inhibitor of the mitogen protein kinase p38 is a small molecular inhibitor which can effectively inhibit the synthesis of in vivo TNF (tumor necrosis factor)-alpha, has the curative effect of a large molecular inhibitor on diseases, is low in production cost, can be orally taken so that a patient can conveniently use the inhibitor, has good practicability, and can generate good economic and social effects.

The invention provides a primer group, an application, a product and a method for detecting SNP (single nucleotide polymorphism) loci related to drug metabolism capacity of rheumatic immunological diseases, and relates to the technical field of biology. The primer group for detecting the SNP loci related to the drug metabolism capacity of the rheumatic immunological diseases can be used for detecting metabolism capacity of an immunosuppressor, metabolism capacity of an immunomodulator, metabolism capacity of an anti-inflammatory agent, metabolism capacity of a TNF inhibitor, metabolism capacity of a B cell regulator, metabolism capacity of an IL-6 inhibitor, metabolism capacity of a uric acid lowering agent and metabolism capacity of a uricosuric agent. The primer group is designed for main mutation sites related to common drug metabolism of the rheumatic immunological diseases, can realize specific detection for locus mutation related to common drug metabolism of the rheumatic immunological diseases, and can greatly shorten detection cycle and reduce detection cost.

Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and / or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNFalpha agent and methods of determining the efficacy of treatment with an anti-TNFalpha agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNFalpha agent.

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Provided herein, inter alia, are pharmaceutical compositions methods thereof that include a first amount of a PTPRS de-clustering agent and a second amount of a TNF inhibitor or an IL-6 inhibitor in synergistic amounts. The synergistic combinations provide (a) amelioration of disease or one or more symptoms of disease or (b) delay of onset of disease or one or more symptoms of disease.

The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

The invention discloses an inhibitor of mitogen protein kinase p38 as well as a preparation method and application of the inhibitor. The inhibitor is an amino nicotinamide compound or an amino pyrazinamide compound. The preparation method mainly comprises the following steps: nitrifying 6-hydroxyl nicotinic acid to generate 5-nitro-6-hydroxyl nicotinic acid; treating 5-nitro-6-hydroxyl nicotinic acid with phosphorus oxybromide so as to convert 5-nitro-6-hydroxyl nicotinic acid into 5-nitro-6-bromonicotinic acid; carrying out Suzuki coupling reaction on 5-nitro-6-bromonicotinic acid to generate 5-nitro-6-aryl nicotinic acid; reacting 5-nitro-6-aryl nicotinic acid with oxalyl chloride to obtain 5-nitro-6-aryl nicotinamide; and carrying out hydrogenation reduction on a nitro group to obtain 5-amino-6-aryl nicotinamide. According to the invention, the inhibitor of the mitogen protein kinase p38 is a small molecular inhibitor which can effectively inhibit the synthesis of in vivo TNF (tumor necrosis factor)-alpha, has the curative effect of a large molecular inhibitor on diseases, is low in production cost, can be orally taken so that a patient can conveniently use the inhibitor, has good practicability, and can generate good economic and social effects.

A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and / or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-α, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.